{"meta":{"query_hash":"53650d73b94e","filters":{"venue":"Human Vaccines"},"cohort_total":29,"direct_labels_cover":0,"predictions_cover":29,"exported":29,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/53650d73b94e","api":"https://metacan.xera.ac/api/v1/cohort?venue=Human+Vaccines"},"results":[{"id":"W1970117165","doi":"10.4161/hv.6.2.10299","title":"Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine","year":2010,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut National de Santé Publique du Québec","funders":"Merck Canada","keywords":"Titer; Medicine; Vaccination; Booster dose; Booster (rocketry); Hepatitis B; Persistence (discontinuity); Hepatitis B vaccine; Immunology; Antibody; Immune system; Immunological memory; Immunity; Internal medicine; Hepatitis B virus; HBsAg; Virus","score_opus":0.010439866014861467,"score_gpt":0.26680962344140435,"score_spread":0.2563697574265429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970117165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99963987,0.00019102772,0.000009050248,0.00000808383,0.0000019607583,0.0000040434243,0.000020406214,6.01942e-7,0.00012504998],"genre_scores_gemma":[0.999196,0.0001937289,0.000030987783,0.000040963605,0.000005267604,0.0000073319757,0.00008712739,8.101231e-7,0.00043770915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998524,0.000033557862,0.000009992301,0.00002269195,0.00002934924,0.0000519356],"domain_scores_gemma":[0.9992061,0.00017518774,0.00026167577,0.000038020422,0.000105060884,0.00021388702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006197317,0.00018132938,0.00029689906,0.00030335147,0.00020186481,0.0003526495,0.00016749615,0.00032066493,0.0012027771],"category_scores_gemma":[0.0012323803,0.00017666124,0.00021997686,0.00011339234,0.00020650418,0.00031464818,0.0001402994,0.0005959538,0.00021701366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037209447,0.0018730796,0.94420767,0.00018842172,0.00011355001,0.0005545987,0.0010305701,0.000055220662,0.029470447,0.000054814187,0.00021846672,0.018512152],"study_design_scores_gemma":[0.000052289997,0.00593821,0.9916079,0.000022942622,0.000033396762,0.00026997837,0.00032467738,0.0000488149,0.0013744127,0.000016135733,0.00030641025,0.0000047674575],"about_ca_topic_score_codex":0.003216871,"about_ca_topic_score_gemma":0.004255769,"teacher_disagreement_score":0.003216871,"about_ca_system_score_codex":0.00026055533,"about_ca_system_score_gemma":0.00029919588,"threshold_uncertainty_score":0.0063962936},"labels":[],"label_agreement":null},{"id":"W1970168773","doi":"10.4161/hv.6.3.10298","title":"High titer human immunoglobulin as a specific therapy against West Nile virus encephalitis","year":2010,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Japanese encephalitis; Virology; Disease; Immunology; Virus; Encephalitis; Asymptomatic; Population; Medicine; Antibody; Culex; Flavivirus; Biology; Environmental health; Internal medicine","score_opus":0.014213545713008228,"score_gpt":0.28322751211124525,"score_spread":0.26901396639823705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970168773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89424723,0.051363226,0.01579494,0.0017588093,0.001840872,0.0010694681,0.00037924704,0.00079850934,0.032747626],"genre_scores_gemma":[0.96783364,0.011866611,0.0031477879,0.00092453975,0.00028649985,0.00024401181,0.00041212453,0.000021646461,0.015263216],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998982,0.00004244248,0.0000042821134,0.00001027212,0.000022675702,0.000022180648],"domain_scores_gemma":[0.99996567,0.000012585145,0.0000049232085,0.0000040458917,0.0000039848337,0.0000088868355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035408713,0.00028146675,0.00027589183,0.0003233517,0.00013846438,0.00019391766,0.00034632755,0.00058721576,0.0024256606],"category_scores_gemma":[0.0001637441,0.000057952333,0.00021293567,0.00016033363,0.00020408323,0.00025698903,0.00014151198,0.0007634832,0.00056581554],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009295088,0.011712582,0.0015735857,0.00089040806,0.00025523614,0.0012516254,0.00016150298,0.0010826493,0.34384847,0.0030279518,0.010222355,0.61667866],"study_design_scores_gemma":[0.01610802,0.23791113,0.035147298,0.0004978652,0.00067986693,0.010514712,0.00020254825,0.00546999,0.43178645,0.0032277775,0.2583733,0.00008098999],"about_ca_topic_score_codex":0.00035395232,"about_ca_topic_score_gemma":0.0005033274,"teacher_disagreement_score":0.0024256606,"about_ca_system_score_codex":0.00017635275,"about_ca_system_score_gemma":0.00019481109,"threshold_uncertainty_score":0.008114696},"labels":[],"label_agreement":null},{"id":"W1971945861","doi":"10.4161/hv.7.4.14141","title":"Acute otitis media and its prevention by immunization: A survey of Canadian pediatricians’ knowledge, attitudes and beliefs","year":2011,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut National de Santé Publique du Québec","funders":"GlaxoSmithKline","keywords":"Medicine; Acute otitis media; Immunization; Otitis; Medical prescription; Family medicine; Pediatrics; Adverse effect; Multivariate analysis; Pneumococcal conjugate vaccine; Immunology; Antibiotics; Internal medicine; Streptococcus pneumoniae; Surgery","score_opus":0.05734017980258541,"score_gpt":0.3039299727532077,"score_spread":0.2465897929506223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971945861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631125,0.00030680522,0.000026239275,0.00038618981,0.000007580789,0.000047915808,0.0012012323,0.0000041812655,0.001708666],"genre_scores_gemma":[0.99797326,0.00066921016,0.00010626893,0.00021013297,0.00000998898,0.000026593014,0.0006143674,0.0000020861744,0.00038805927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986186,0.00010666064,0.0000898805,0.00007864062,0.00073917926,0.0003670082],"domain_scores_gemma":[0.9972103,0.00024972312,0.00082042546,0.000041413758,0.0010060119,0.0006720928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012473654,0.000247994,0.00030182852,0.0010467776,0.00135696,0.00074413285,0.00060644175,0.0005006438,0.0020657051],"category_scores_gemma":[0.0035723026,0.00031156937,0.00051284564,0.0024938877,0.00055288716,0.0004296238,0.000499701,0.00068506616,0.0002877827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029598943,0.000066504326,0.992993,0.000046375946,0.000014494848,0.00006581597,0.0019879013,0.000026537966,0.000105457446,0.000021837343,0.00077929714,0.0038633805],"study_design_scores_gemma":[0.0000040356654,0.000043740092,0.9970931,0.000022260352,0.000005106978,0.00004645725,0.0021099448,0.00006645663,0.000020822154,0.0000033256847,0.0005804826,0.000004261163],"about_ca_topic_score_codex":0.9275808,"about_ca_topic_score_gemma":0.91754526,"teacher_disagreement_score":0.072419226,"about_ca_system_score_codex":0.0077190744,"about_ca_system_score_gemma":0.009422219,"threshold_uncertainty_score":0.1456914},"labels":[],"label_agreement":null},{"id":"W1992463335","doi":"10.4161/hv.6.4.10867","title":"Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines","year":2010,"lang":"en","type":"article","venue":"Human Vaccines","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Immunogenicity; Medicine; HIV vaccine; Adjuvant; Vaccination; Clinical trial; Immunology; AIDS Vaccines; Vaccine trial; Virology; Human immunodeficiency virus (HIV); Immune system; Internal medicine","score_opus":0.018784717563056875,"score_gpt":0.3033413365913008,"score_spread":0.2845566190282439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992463335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83209676,0.12050946,0.035754353,0.0029976883,0.0011937452,0.0005263393,0.00034049017,0.00023097312,0.006350138],"genre_scores_gemma":[0.9240997,0.036898036,0.03142239,0.00051499286,0.00045058667,0.00019466467,0.0003418016,0.000027201891,0.0060506444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987113,0.0000481921,0.0000109263965,0.000012674261,0.000029087194,0.000027963866],"domain_scores_gemma":[0.9999012,0.000022078842,0.000021659338,0.000007173059,0.000022657396,0.000025252515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006154346,0.00024411548,0.00023976459,0.00031140813,0.00009016407,0.00027446513,0.00018868138,0.00037328713,0.00064317207],"category_scores_gemma":[0.00026595246,0.00010226074,0.0002510795,0.00009755741,0.00017862026,0.00030117633,0.00015960664,0.0007052486,0.0001930259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001652532,0.0007159852,0.0011535455,0.0008592934,0.000063084255,0.0003077387,0.00011358774,0.0029379716,0.78627735,0.0034904203,0.0012344545,0.20119412],"study_design_scores_gemma":[0.0014049192,0.020365816,0.0024199532,0.0002658255,0.00014921815,0.0016256957,0.00008819611,0.004870062,0.85591274,0.002064553,0.11080115,0.00003197482],"about_ca_topic_score_codex":0.00022327965,"about_ca_topic_score_gemma":0.00040533222,"teacher_disagreement_score":0.00064317207,"about_ca_system_score_codex":0.00024036012,"about_ca_system_score_gemma":0.00023321013,"threshold_uncertainty_score":0.0032547712},"labels":[],"label_agreement":null},{"id":"W2000061294","doi":"10.4161/hv.7.7.15579","title":"Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults","year":2011,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; University of California, San Francisco","keywords":"Medicine; Reactogenicity; Tolerability; Placebo; Adverse effect; Vaccination; Internal medicine; Incidence (geometry); Randomized controlled trial; Immunology; Immunogenicity; Antibody","score_opus":0.04165342418886398,"score_gpt":0.31942577559278473,"score_spread":0.27777235140392076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000061294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974292,0.0019973833,0.00006174683,0.000044704328,0.000014475717,0.000051357543,0.00012130186,0.0000028745615,0.000276936],"genre_scores_gemma":[0.9985172,0.00087870803,0.00011479037,0.00010421763,0.00003494094,0.000047084894,0.0001387793,9.4519925e-7,0.00016327109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960023,0.0001899295,0.00004935691,0.000036347752,0.00008864398,0.00003557908],"domain_scores_gemma":[0.9986658,0.00036088147,0.00061630213,0.000038089405,0.00013742382,0.00018152958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001613509,0.00022171573,0.00055192446,0.00021011716,0.00015088,0.00020873497,0.00010084268,0.0003585737,0.0008874387],"category_scores_gemma":[0.0018162817,0.00013128355,0.00056312274,0.00014391309,0.00012552123,0.00016504925,0.00013110567,0.0003837016,0.0001314523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09077948,0.0039954,0.71601385,0.001627029,0.0016539425,0.00038345985,0.0008659483,0.00065255526,0.03594621,0.00007623708,0.0007173616,0.14728853],"study_design_scores_gemma":[0.0036229847,0.107787095,0.88124776,0.00013877131,0.00071923004,0.00052856526,0.00015831899,0.0002846713,0.0037530165,0.00005326438,0.0016948959,0.000011321438],"about_ca_topic_score_codex":0.00038260437,"about_ca_topic_score_gemma":0.00042229707,"teacher_disagreement_score":0.001613509,"about_ca_system_score_codex":0.00013430792,"about_ca_system_score_gemma":0.00017396198,"threshold_uncertainty_score":0.00853318},"labels":[],"label_agreement":null},{"id":"W2002056847","doi":"10.4161/hv.1.4.1990","title":"Potency of Cell-Mediated Immune Responses to Different Combined HIV-1 Immunogens in a Humanized Murine Model","year":2005,"lang":"en","type":"article","venue":"Human Vaccines","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Potency; Humanized mouse; Immune system; Immunology; Human immunodeficiency virus (HIV); Virology; Biology; In vitro","score_opus":0.019423284431976027,"score_gpt":0.27217852561726674,"score_spread":0.2527552411852907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002056847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927126,0.0022206365,0.0032548935,0.000112299975,0.00008517453,0.00017262745,0.00019560731,0.000084305066,0.0011618725],"genre_scores_gemma":[0.993288,0.0011510671,0.0031271914,0.00010289763,0.000062255654,0.00019829233,0.00039813307,0.00001758101,0.001654651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99937195,0.00022606619,0.000028955848,0.00015012524,0.000115303534,0.000107649714],"domain_scores_gemma":[0.9997968,0.000057541973,0.00003636444,0.00005188153,0.000014711027,0.000042802283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007866244,0.0011473065,0.0005292562,0.00054416445,0.00018446734,0.0004890101,0.000326414,0.000678078,0.0015045883],"category_scores_gemma":[0.00023008753,0.00026244792,0.0003797225,0.00015110936,0.00041442158,0.0005098753,0.00024011436,0.0016829915,0.00043729876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016849894,0.0013454235,0.00033527022,0.00007396016,0.000022423574,0.00009536551,0.0000367959,0.0003384979,0.99088365,0.00011413093,0.00010297094,0.004966393],"study_design_scores_gemma":[0.0004291035,0.03888794,0.0020221164,0.00002909118,0.000099333534,0.0010096341,0.000042123487,0.001656573,0.9527086,0.00018749756,0.0029140394,0.000013866922],"about_ca_topic_score_codex":0.00015007319,"about_ca_topic_score_gemma":0.00017861363,"teacher_disagreement_score":0.0015045883,"about_ca_system_score_codex":0.0002831214,"about_ca_system_score_gemma":0.00021643548,"threshold_uncertainty_score":0.005033374},"labels":[],"label_agreement":null},{"id":"W2005791824","doi":"10.4161/hv.7.2.13690","title":"Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines","year":2011,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"GlaxoSmithKline","keywords":"Bivalent (engine); Immunogenicity; Medicine; Vaccination; Booster dose; Virology; Immune system; Cervical cancer; Immunology; HPV vaccines; HPV infection; Immunization; Internal medicine; Cancer","score_opus":0.14155396687683644,"score_gpt":0.39794047132170157,"score_spread":0.2563865044448651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005791824","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007521219,0.9994815,0.000032855798,0.000071673516,0.0000553387,0.000003385302,0.000012411863,0.0000027797173,0.0002648939],"genre_scores_gemma":[0.00036899763,0.99931645,0.000072702496,0.000046904817,0.000042166193,0.0000050851927,0.000017776678,5.112455e-7,0.00012941773],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997733,0.00004387068,0.00004571955,0.000037065623,0.000080934995,0.00001909553],"domain_scores_gemma":[0.9995407,0.00025024608,0.00008196848,0.000009791869,0.0000913113,0.000026105625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006921554,0.00092557096,0.0018431892,0.0021725006,0.00021663388,0.0006925116,0.00097154046,0.00088252564,0.0037295618],"category_scores_gemma":[0.00095121516,0.00035910856,0.0006510464,0.0024180596,0.0002963035,0.0011439965,0.00041818133,0.00095066335,0.0014328067],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119382836,0.00006991961,0.00020325996,0.04410264,0.00016207677,0.00011915228,0.000041532487,0.00023298468,0.0010251631,0.0008864908,0.018374333,0.934663],"study_design_scores_gemma":[0.0000631642,0.00029906066,0.0025271452,0.022144167,0.00066709577,0.0018275426,0.00010569492,0.000107670465,0.00074172625,0.0013750285,0.97011024,0.000031533298],"about_ca_topic_score_codex":0.0011947961,"about_ca_topic_score_gemma":0.0019586019,"teacher_disagreement_score":0.0037295618,"about_ca_system_score_codex":0.00047629152,"about_ca_system_score_gemma":0.0009965309,"threshold_uncertainty_score":0.012476623},"labels":[],"label_agreement":null},{"id":"W2014047240","doi":"10.4161/hv.6.9.11561","title":"Recent advances in the development of novel mucosal adjuvants and antigen delivery systems","year":2010,"lang":"en","type":"article","venue":"Human Vaccines","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute for Biological Sciences; Brock University","funders":"","keywords":"Adjuvant; Medicine; Mucosal immunity; Immunization; Immunology; Mucosal immunology; Vaccination; Vaccine adjuvant; Immune system; Antigen; Immunity","score_opus":0.021354511710913095,"score_gpt":0.2824016329974406,"score_spread":0.2610471212865275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014047240","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018712659,0.9917528,0.0025027043,0.00044949952,0.0003117373,0.000024591272,0.000047192174,0.000037510916,0.0030027525],"genre_scores_gemma":[0.0064197793,0.9869489,0.0032874737,0.0004880241,0.0005465718,0.000040162115,0.00012628865,0.000009818599,0.0021330894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968886,0.0000493967,0.00004312321,0.00007104487,0.00010454809,0.00004305602],"domain_scores_gemma":[0.99939287,0.00026095827,0.00011708691,0.000023773951,0.00015366907,0.000051535317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000986565,0.000906726,0.00073544146,0.0013841565,0.00025222663,0.00090583396,0.0006905668,0.0010478717,0.004084369],"category_scores_gemma":[0.0007496822,0.00040805535,0.00045269972,0.0014807303,0.00035517916,0.0013706987,0.00067485776,0.0015466567,0.0017748474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001786019,0.00030115526,0.0004327683,0.025705704,0.00009473596,0.00041242596,0.00020121277,0.0015949402,0.044296786,0.007960678,0.013762244,0.9050588],"study_design_scores_gemma":[0.000024898636,0.00063800137,0.00092444,0.0014772094,0.00015529641,0.0013455694,0.00007983072,0.0007812649,0.022409994,0.0017945776,0.97031724,0.000051692532],"about_ca_topic_score_codex":0.00052619586,"about_ca_topic_score_gemma":0.0005588037,"teacher_disagreement_score":0.004084369,"about_ca_system_score_codex":0.0004681359,"about_ca_system_score_gemma":0.00086941675,"threshold_uncertainty_score":0.01366359},"labels":[],"label_agreement":null},{"id":"W2017096286","doi":"10.4161/hv.7.12.18322","title":"Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule","year":2011,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; University of Alberta","funders":"Merck","keywords":"Medicine; Immunogenicity; Schedule; Titer; Internal medicine; Vaccination; Gastroenterology; Antigen; Antibody; Immunology","score_opus":0.08895439800482836,"score_gpt":0.3512983015467438,"score_spread":0.26234390354191545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017096286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831724,0.00061526557,0.00015925955,0.0000341512,0.00006987739,0.0003254778,0.00015375597,0.000012388872,0.00031268672],"genre_scores_gemma":[0.996867,0.00045243898,0.0005523562,0.00010436528,0.00012515273,0.00073591707,0.0002497062,0.000007407749,0.00090559677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99907756,0.00046006805,0.000066998036,0.00015466518,0.00013619664,0.0001044467],"domain_scores_gemma":[0.998928,0.0002982609,0.0003448252,0.00010618371,0.00008147003,0.00024116084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016054759,0.00059867935,0.0016787747,0.00029309661,0.00016210917,0.0005542445,0.0005674655,0.0010601423,0.0023430276],"category_scores_gemma":[0.0016911686,0.00035370252,0.0007687778,0.00027734684,0.0006030429,0.00060240494,0.00022279713,0.0012028557,0.00041436986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91571385,0.024017712,0.0018642624,0.000311428,0.00027744716,0.00003098592,0.00005905789,0.00052830105,0.032411452,0.00010961978,0.00023197125,0.02444391],"study_design_scores_gemma":[0.102264136,0.8810182,0.0074271807,0.000030339344,0.00031565398,0.000059235575,0.000028799817,0.00086210144,0.0071913665,0.00013480763,0.0006446757,0.00002349649],"about_ca_topic_score_codex":0.00038692245,"about_ca_topic_score_gemma":0.00035274398,"teacher_disagreement_score":0.0023430276,"about_ca_system_score_codex":0.00044424675,"about_ca_system_score_gemma":0.0007789165,"threshold_uncertainty_score":0.008490682},"labels":[],"label_agreement":null},{"id":"W2035039470","doi":"10.4161/hv.1.4.1971","title":"Canadian Association for Immunization Research and Evaluation (CAIRE) Guidelines for Industry Sponsored Clinical Trial and Epidemiology Contract Research","year":2005,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Wyeth Pharmaceuticals","keywords":"Epidemiology; Protocol (science); Clinical trial; Association (psychology); Medicine; Immunization; Family medicine; Public health; Environmental health; Business; Alternative medicine; Pathology; Immunology; Psychology","score_opus":0.70834095780831,"score_gpt":0.6420046208395551,"score_spread":0.06633633696875485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035039470","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004178044,0.038124755,0.19913496,0.22987674,0.034168575,0.19970584,0.028981851,0.0041411635,0.26168796],"genre_scores_gemma":[0.02454593,0.025978368,0.6888847,0.084294245,0.0046454407,0.09797649,0.018000241,0.0011298714,0.054544777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.5531644,0.23522668,0.08269557,0.005703985,0.11299537,0.010213944],"domain_scores_gemma":[0.29660857,0.20158386,0.044960853,0.04305176,0.3951612,0.018633744],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.45059788,0.0020676316,0.0044834423,0.013101349,0.007660678,0.00975797,0.013014927,0.01236215,0.014421288],"category_scores_gemma":[0.46545672,0.0041427757,0.005632599,0.022259021,0.0065634255,0.0032795896,0.0050290865,0.018892149,0.0062507303],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072321435,0.00045025404,0.0027462256,0.0063947183,0.00037114604,0.00028257567,0.0019464799,0.0011175871,0.00072316744,0.0448345,0.8363213,0.10408887],"study_design_scores_gemma":[0.0020361436,0.0005144248,0.02308011,0.012820707,0.0006251916,0.00032033995,0.0009108425,0.002408506,0.0010659343,0.013901815,0.9418729,0.000443084],"about_ca_topic_score_codex":0.48756978,"about_ca_topic_score_gemma":0.679094,"teacher_disagreement_score":0.9624539,"about_ca_system_score_codex":0.037546087,"about_ca_system_score_gemma":0.33277953,"threshold_uncertainty_score":0.9694636},"labels":[],"label_agreement":null},{"id":"W2035983041","doi":"10.4161/hv.4.3.5686","title":"The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia","year":2008,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"Merck Canada; Université Laval; GlaxoSmithKline","keywords":"Medicine; Vaccination; Cost effectiveness; Population; Quality-adjusted life year; Vaccine efficacy; Pediatrics; Cohort; Environmental health; Immunology; Internal medicine","score_opus":0.023855172607118853,"score_gpt":0.29800767275606166,"score_spread":0.2741525001489428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035983041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89442116,0.025507046,0.030027917,0.006949356,0.00017633715,0.0012654111,0.008424605,0.00012600781,0.033102166],"genre_scores_gemma":[0.9903548,0.0035894306,0.0026147543,0.00023628217,0.000015392507,0.00009380566,0.0008546624,0.0000070509745,0.002233929],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998701,0.00068714004,0.00004688447,0.00008235295,0.00024197399,0.00024069435],"domain_scores_gemma":[0.9978502,0.0015488556,0.0002104273,0.000052956108,0.0002136746,0.00012393031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031577742,0.0006974114,0.0008223683,0.00075635215,0.00036385746,0.0015651016,0.0012194193,0.0009729155,0.003059374],"category_scores_gemma":[0.01030104,0.00045873862,0.002036802,0.0010644824,0.000579788,0.00096982403,0.00061369524,0.0010230824,0.00015602163],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028761413,0.00026708795,0.048820607,0.0010197064,0.0024857728,0.0004650042,0.00013648049,0.8532599,0.0008419156,0.019164473,0.0019075185,0.068755426],"study_design_scores_gemma":[0.0012354628,0.0025003226,0.13090058,0.0011095676,0.0068797977,0.00126074,0.000399185,0.8162739,0.0013511817,0.02352779,0.014405786,0.00015564817],"about_ca_topic_score_codex":0.3902673,"about_ca_topic_score_gemma":0.3295504,"teacher_disagreement_score":0.3902673,"about_ca_system_score_codex":0.012401396,"about_ca_system_score_gemma":0.013006153,"threshold_uncertainty_score":0.77599144},"labels":[],"label_agreement":null},{"id":"W2040474024","doi":"10.4161/hv.5.11.9309","title":"In Memoriam, Bernard Duval (1949 – 2008)","year":2009,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Travel-related health issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de Santé Publique du Québec","funders":"","keywords":"Philosophy; Medicine","score_opus":0.02820136364870216,"score_gpt":0.35562245612380156,"score_spread":0.3274210924750994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040474024","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012456224,0.012693456,0.0001276551,0.43521073,0.55112684,0.0000142584795,0.00008936921,0.00003462074,0.00057856046],"genre_scores_gemma":[0.0020173348,0.0077736476,0.00022089775,0.5877791,0.38448566,0.000062973355,0.00007812274,0.0000505105,0.017531749],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963104,0.0006533787,0.00053678366,0.0009806838,0.0010717864,0.00044684156],"domain_scores_gemma":[0.9852248,0.0052192966,0.0019049734,0.0004987146,0.0044383975,0.0027137743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005756938,0.0026825378,0.0031581859,0.0015950887,0.004966348,0.008615373,0.0029762154,0.028784588,0.007632994],"category_scores_gemma":[0.043065745,0.00092520897,0.0022099717,0.0009175163,0.0034188777,0.0052364618,0.0062264446,0.036946002,0.0077863727],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028523233,0.000010053089,0.00017834027,0.00008561545,0.000021474994,0.00022549291,0.00012282892,0.000026095506,0.00007408255,0.0003452747,0.9953434,0.0035388274],"study_design_scores_gemma":[0.00002521922,0.000023977525,0.00093482767,0.0002971736,0.00003786846,0.00042733006,0.0003193603,0.00009566154,0.00011912313,0.00068998494,0.9969908,0.000038665505],"about_ca_topic_score_codex":0.010700156,"about_ca_topic_score_gemma":0.016972288,"teacher_disagreement_score":0.028784588,"about_ca_system_score_codex":0.005001335,"about_ca_system_score_gemma":0.005298056,"threshold_uncertainty_score":0.036287427},"labels":[],"label_agreement":null},{"id":"W2043876053","doi":"10.4161/hv.6.12.12917","title":"Searching for the Holy Grail of a staphylococcal vaccine","year":2010,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Antimicrobial Resistance in Staphylococcus","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Holy Grail; Staphylococcus aureus; Immunology; Colonization; Medicine; Staphylococcal infections; Virology; Microbiology; Biology; Computer science; Bacteria","score_opus":0.07428239513320778,"score_gpt":0.39652541617909515,"score_spread":0.32224302104588737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043876053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007985486,0.99530953,0.00009245621,0.0030218803,0.0008629981,0.0000017669901,0.000005327291,0.0000040492737,0.00062212173],"genre_scores_gemma":[0.00059604115,0.9957159,0.00018225469,0.0018091996,0.0008122363,0.0000034776435,0.000009918181,0.0000012519276,0.0008696345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995264,0.00014953154,0.000052152896,0.000044071625,0.00019465982,0.00003313232],"domain_scores_gemma":[0.99933285,0.0003495948,0.00008934787,0.000019435514,0.00015140226,0.00005737918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009521192,0.0006937324,0.0013335636,0.0014154736,0.00033973716,0.0012695949,0.000691356,0.0021818827,0.0027708418],"category_scores_gemma":[0.0015267251,0.0002311066,0.00042496095,0.001349782,0.00088015205,0.0029204562,0.0005324074,0.002726827,0.0018412907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012688135,0.000095799274,0.00026677764,0.017325442,0.00014961488,0.00048964866,0.00017669707,0.00036718592,0.0044228463,0.015374228,0.1613288,0.79987603],"study_design_scores_gemma":[0.000022465116,0.00007169836,0.00039237647,0.003875855,0.000049151364,0.0011682246,0.00012897032,0.00007197144,0.00051559263,0.0056187785,0.9880695,0.000015475782],"about_ca_topic_score_codex":0.0011749689,"about_ca_topic_score_gemma":0.0024652046,"teacher_disagreement_score":0.0027708418,"about_ca_system_score_codex":0.00092259806,"about_ca_system_score_gemma":0.0016645407,"threshold_uncertainty_score":0.009269416},"labels":[],"label_agreement":null},{"id":"W2048546608","doi":"10.4161/hv.6.8.12299","title":"Development of a Chlamydia trachomatis T cell Vaccine","year":2010,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Reproductive tract infections research","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Chlamydia trachomatis; Immunology; Immunity; Antigen; Chlamydia; Biology; Immune system; Intracellular parasite; Virology; Cellular immunity; Acquired immune system","score_opus":0.06287883281366984,"score_gpt":0.36704394158064896,"score_spread":0.3041651087669791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048546608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012409212,0.99275756,0.0010094576,0.0004574137,0.00048282483,0.000026688123,0.00003889036,0.000023349565,0.003962841],"genre_scores_gemma":[0.0034388744,0.9916161,0.001237816,0.00032250688,0.00016516478,0.000027534865,0.00007195353,0.0000033096694,0.003116777],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989307,0.000015555019,0.000010789825,0.000019113013,0.00004548716,0.00001585318],"domain_scores_gemma":[0.9999385,0.000017046183,0.000010055358,0.000002783424,0.0000211408,0.000010625498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033783316,0.0007450244,0.0009787789,0.0009626463,0.00020039486,0.0005726178,0.000587732,0.0011696635,0.0023454074],"category_scores_gemma":[0.00023704307,0.00031278067,0.0003369952,0.0008082993,0.00025656063,0.00092053466,0.000361131,0.0012999573,0.0022801796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097020384,0.0001388285,0.00019172425,0.010239815,0.00006370086,0.00038412763,0.000052528187,0.0007678733,0.03203524,0.0058898362,0.021403547,0.9287358],"study_design_scores_gemma":[0.000040056908,0.00023485637,0.00075088267,0.0012906105,0.00006287608,0.0011766225,0.000033489778,0.00019963332,0.008799118,0.0014973285,0.98589873,0.000015741825],"about_ca_topic_score_codex":0.0009338137,"about_ca_topic_score_gemma":0.0011204953,"teacher_disagreement_score":0.0023454074,"about_ca_system_score_codex":0.0006908074,"about_ca_system_score_gemma":0.0007396773,"threshold_uncertainty_score":0.007846177},"labels":[],"label_agreement":null},{"id":"W2049906117","doi":"10.4161/hv.5.3.7557","title":"AIDS Vaccine 2008 Conference","year":2009,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Hogan; Library science; Human immunodeficiency virus (HIV); Political science; Government (linguistics); Medicine; Family medicine; Sociology","score_opus":0.037078292322065005,"score_gpt":0.3262082186977579,"score_spread":0.2891299263756929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049906117","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035373487,0.041758776,0.002358238,0.10587814,0.14388213,0.00088992354,0.008726405,0.0011027065,0.6918664],"genre_scores_gemma":[0.016895877,0.028102122,0.003375909,0.03721587,0.020036796,0.0008924946,0.013261415,0.00042769278,0.8797919],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982035,0.00037111473,0.00009766881,0.00022147186,0.0007992514,0.0003069014],"domain_scores_gemma":[0.997678,0.00019098492,0.0001066354,0.00008057188,0.0013198378,0.0006239805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026276133,0.0012284144,0.0006014592,0.0015260907,0.0016694091,0.0041530062,0.0017706057,0.003008143,0.2600939],"category_scores_gemma":[0.004731815,0.00025832295,0.0008275723,0.0008118806,0.00035790997,0.0017929102,0.002127542,0.0032206255,0.13504565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005390254,0.000039480794,0.00009850137,0.00021623635,0.0000051696147,0.00005648453,0.000045033306,0.000031033665,0.00019160348,0.0013111315,0.93431675,0.063634686],"study_design_scores_gemma":[0.0000114876375,0.000022795472,0.00014450305,0.00012128256,0.0000035741489,0.000057191293,0.000034543944,0.000012760177,0.00011654146,0.00027808174,0.99919444,0.0000028392465],"about_ca_topic_score_codex":0.002262145,"about_ca_topic_score_gemma":0.0042629363,"teacher_disagreement_score":0.2600939,"about_ca_system_score_codex":0.002194548,"about_ca_system_score_gemma":0.005115765,"threshold_uncertainty_score":0.87010074},"labels":[],"label_agreement":null},{"id":"W2057104007","doi":"10.4161/hv.7.6.15007","title":"Increasing pandemic vaccination rates with effective communication","year":2011,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Misinformation and Its Impacts","field":"Social Sciences","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; Centre for Health Evaluation and Outcome Sciences","funders":"","keywords":"Public health; Pandemic; Public relations; Vaccination; Health communication; Information Dissemination; Social media; Internet privacy; Medicine; Business; Coronavirus disease 2019 (COVID-19); Political science; Disease; Infectious disease (medical specialty); Computer science; Immunology; Nursing","score_opus":0.05845645706609882,"score_gpt":0.3460264004311486,"score_spread":0.28756994336504976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057104007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44413403,0.024005132,0.06290234,0.108143486,0.003353236,0.0015699537,0.002787193,0.002543199,0.35056144],"genre_scores_gemma":[0.9614229,0.0058305454,0.016903397,0.0053564846,0.0020178498,0.00054436165,0.000498465,0.00011731905,0.0073087285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955519,0.0027100693,0.00028795845,0.00034135225,0.0006363712,0.00047235427],"domain_scores_gemma":[0.9776904,0.012601646,0.004354333,0.0015734896,0.0025183843,0.0012617374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068059294,0.00051927834,0.000424136,0.0018806063,0.00054347044,0.0021226197,0.0009667543,0.0016119304,0.02906703],"category_scores_gemma":[0.059654757,0.00029671003,0.000804527,0.0011380597,0.00060871843,0.004275161,0.0022147556,0.0018279447,0.0051801773],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007277355,0.0012861335,0.12053705,0.0018108317,0.00023568886,0.00041262832,0.0038170163,0.004484468,0.0026499627,0.018181186,0.04735082,0.7985066],"study_design_scores_gemma":[0.0007161128,0.0043302663,0.6145527,0.004191608,0.0010360373,0.0049787043,0.009324074,0.020302413,0.010059686,0.1000518,0.2302329,0.0002236504],"about_ca_topic_score_codex":0.0016521134,"about_ca_topic_score_gemma":0.0009900338,"teacher_disagreement_score":0.02906703,"about_ca_system_score_codex":0.0009554168,"about_ca_system_score_gemma":0.0013401392,"threshold_uncertainty_score":0.09723896},"labels":[],"label_agreement":null},{"id":"W2064091377","doi":"10.4161/hv.1.1.1553","title":"A Phase I, Randomized, Controlled Trial to Study the Reactogenicity and Immunogenicity of a Nasal, Inactivated Trivalent Influenza Virus Vaccine in Healthy Adults","year":2005,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Reactogenicity; Immunogenicity; Medicine; Virology; Nasal administration; Trivalent influenza vaccine; Influenza vaccine; Virus; Influenza A virus; Randomized controlled trial; Immunology; Internal medicine; Antibody","score_opus":0.07541509844375696,"score_gpt":0.42656770876693034,"score_spread":0.35115261032317335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064091377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731347,0.0064617717,0.0016981538,0.00096834503,0.0011665643,0.01360593,0.00090785424,0.00019480118,0.0018619613],"genre_scores_gemma":[0.9586047,0.0042176205,0.005660942,0.0029072415,0.0012484813,0.022749916,0.0010861842,0.000040156254,0.0034847974],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987739,0.0006774292,0.00009813115,0.00024013915,0.00008933077,0.00012115223],"domain_scores_gemma":[0.99814105,0.0006454775,0.00044247162,0.00017329553,0.00014705214,0.0004505519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028135106,0.0018531336,0.003571573,0.0004883364,0.00061400037,0.0009310224,0.0010841148,0.0023716153,0.0061071087],"category_scores_gemma":[0.003082474,0.0009208101,0.0015612823,0.00043004128,0.0015451293,0.0011585933,0.00038054024,0.0025888213,0.0010269779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9811553,0.0062869843,0.00035137133,0.00051649177,0.00048760689,0.000026555525,0.000036349822,0.00011579745,0.0023382662,0.00006568407,0.00030588446,0.008313668],"study_design_scores_gemma":[0.9377908,0.061143264,0.00037301364,0.000013466548,0.00015337164,0.000011532024,0.0000070847204,0.00011520301,0.00016263544,0.000042235486,0.00018314477,0.00000428435],"about_ca_topic_score_codex":0.0005806681,"about_ca_topic_score_gemma":0.0010903836,"teacher_disagreement_score":0.0061071087,"about_ca_system_score_codex":0.0004710996,"about_ca_system_score_gemma":0.0012760928,"threshold_uncertainty_score":0.020430386},"labels":[],"label_agreement":null},{"id":"W2065739755","doi":"10.4161/hv.6.12.13399","title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine","year":2010,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"GlaxoSmithKline","keywords":"Antibody; Medicine; Titer; Vaccination; Antibody titer; Immunology; Correlation","score_opus":0.040306430003011186,"score_gpt":0.3432970642834369,"score_spread":0.3029906342804257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065739755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948782,0.0039311037,0.00025711555,0.000021197411,0.000011027854,0.00003439899,0.00043506958,0.000008491033,0.0004233438],"genre_scores_gemma":[0.99849474,0.00049324875,0.0001836861,0.000021672851,0.000013196547,0.00003592671,0.00061622856,0.0000043942055,0.0001368364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849236,0.00068122655,0.00018528158,0.00020983585,0.00034564754,0.00008555343],"domain_scores_gemma":[0.9956762,0.0022317956,0.0012363029,0.00017842067,0.00045867407,0.00021857327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029451377,0.0002771528,0.0012183007,0.00069671555,0.00011495222,0.00045152963,0.00016250041,0.0003106114,0.0006626542],"category_scores_gemma":[0.0057009645,0.00023637459,0.00081796746,0.0005793593,0.00016031758,0.00024845195,0.00027493708,0.00033503378,0.00010729748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011355455,0.0000914385,0.9625448,0.0002761193,0.002412293,0.00008422706,0.00015244496,0.00024932052,0.005926029,0.00001717302,0.00015674862,0.016733913],"study_design_scores_gemma":[0.0002482004,0.0055524264,0.99083203,0.000019577492,0.0010761169,0.00032014164,0.0000683553,0.0002827003,0.0011395565,0.000023464127,0.0004307143,0.0000065441254],"about_ca_topic_score_codex":0.0004520217,"about_ca_topic_score_gemma":0.00065645634,"teacher_disagreement_score":0.0029451377,"about_ca_system_score_codex":0.00017667825,"about_ca_system_score_gemma":0.00021169434,"threshold_uncertainty_score":0.015575588},"labels":[],"label_agreement":null},{"id":"W2073044683","doi":"10.4161/hv.5.2.7210","title":"BCG Vaccines: Their mechanisms of attenuation and impact on safety and protective efficacy","year":2009,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; National Natural Science Foundation of China","keywords":"Virulence; Mycobacterium bovis; Mycobacterium tuberculosis; BCG vaccine; Tuberculosis vaccines; Tuberculosis; Tuberculin; Attenuated vaccine; Biology; Virology; Immunization; Immunology; Vaccination; Microbiology; Medicine; Immune system; Genetics; Gene","score_opus":0.07193749844206884,"score_gpt":0.40676095174401117,"score_spread":0.3348234533019423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073044683","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024056158,0.99883,0.00009027583,0.00016862336,0.00006736992,0.0000027168492,0.0000090239455,0.000003672242,0.0005877723],"genre_scores_gemma":[0.0011524637,0.9982003,0.00013472534,0.00008572195,0.000074501804,0.0000047871304,0.000012425555,7.1748127e-7,0.00033437286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977845,0.000056098845,0.000025905663,0.000033467048,0.00008554876,0.000020511015],"domain_scores_gemma":[0.9996989,0.00015239979,0.00004651789,0.000010635421,0.000067882036,0.000023722427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007547871,0.0006177618,0.001311962,0.0013128995,0.00016698173,0.00069796725,0.0006661681,0.000963412,0.00192029],"category_scores_gemma":[0.0008773332,0.00023822214,0.00031471596,0.0013013106,0.0005095872,0.0010450617,0.0003984316,0.0010789761,0.001376924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013833022,0.000066636676,0.00024016111,0.011507721,0.00005878507,0.0001318195,0.000055326727,0.00034487047,0.0044125062,0.0037504355,0.009063819,0.9702296],"study_design_scores_gemma":[0.000048401773,0.00033715193,0.0024435155,0.003712702,0.00013432353,0.0015931643,0.00008856788,0.0001394743,0.0028273016,0.0030232265,0.9856258,0.000026328067],"about_ca_topic_score_codex":0.0006889238,"about_ca_topic_score_gemma":0.00081619853,"teacher_disagreement_score":0.00192029,"about_ca_system_score_codex":0.0006047457,"about_ca_system_score_gemma":0.00073729403,"threshold_uncertainty_score":0.00642401},"labels":[],"label_agreement":null},{"id":"W2074911236","doi":"10.4161/hv.4.1.4778","title":"Antibody gene-based prophylaxis and therapy for biodefence","year":2008,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Bacillus and Francisella bacterial research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"","keywords":"Antibody; Genetic enhancement; Immunology; Passive immunity; Vaccination; Immunity; Immune system; Medicine; In vivo; Biology; Gene delivery; Transgene; Vectors in gene therapy; Virology; Gene; Vector (molecular biology); Biotechnology; Recombinant DNA; Genetics","score_opus":0.03448213629659268,"score_gpt":0.3098413044306517,"score_spread":0.27535916813405903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074911236","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30004397,0.44937003,0.17449717,0.015918134,0.0022479193,0.0004262564,0.0007359142,0.0011850838,0.05557557],"genre_scores_gemma":[0.8063002,0.1315755,0.030779988,0.0021349173,0.0004279057,0.00023276792,0.00048955786,0.000091364636,0.02796777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981827,0.000045064942,0.0000061918963,0.000029594616,0.00006469418,0.00003623754],"domain_scores_gemma":[0.9999391,0.000011207176,0.000020332434,0.000005443471,0.000013267665,0.000010685082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003131104,0.00034472632,0.00030705085,0.0003415927,0.00014675544,0.00042920784,0.00031845007,0.0007605148,0.0026870088],"category_scores_gemma":[0.000170178,0.00008268184,0.00020985908,0.00024223655,0.0006163057,0.00041009215,0.00024149536,0.0007245354,0.00086169556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003640354,0.00039798446,0.0007773713,0.0009837846,0.000040539744,0.00036936704,0.00016083094,0.00089540536,0.76612306,0.021608584,0.0113154175,0.19696362],"study_design_scores_gemma":[0.00016467005,0.0027828186,0.0022170532,0.00019527535,0.00009854744,0.0024982842,0.00008510159,0.0029502015,0.53767025,0.003280521,0.44801316,0.000044106233],"about_ca_topic_score_codex":0.00082765083,"about_ca_topic_score_gemma":0.0007159741,"teacher_disagreement_score":0.0026870088,"about_ca_system_score_codex":0.0005256465,"about_ca_system_score_gemma":0.00035256767,"threshold_uncertainty_score":0.008988917},"labels":[],"label_agreement":null},{"id":"W2085552858","doi":"10.4161/hv.5.5.7442","title":"Vaccines targeting IgE in the treatment of asthma and allergy","year":2009,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Children's Hospital Research Institute of Manitoba; Manitoba Health","funders":"","keywords":"Omalizumab; Immunoglobulin E; Medicine; Asthma; Immunology; Allergy; Anaphylaxis; Adverse effect; Antibody; Pharmacology","score_opus":0.04369772046502389,"score_gpt":0.34827579179000995,"score_spread":0.30457807132498604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085552858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023612108,0.99792695,0.00012242711,0.00019416494,0.00016247922,0.0000061279497,0.0000067846327,0.0000072216876,0.0013376799],"genre_scores_gemma":[0.0012165809,0.99715316,0.00028358604,0.00018203174,0.00015931753,0.0000066291022,0.000016697983,0.0000012320089,0.0009807246],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998462,0.000032750544,0.000017829545,0.000019329607,0.00006904286,0.000014820368],"domain_scores_gemma":[0.99990165,0.000037659687,0.000017646666,0.0000038593753,0.000026596977,0.000012564768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050255057,0.00062629266,0.00086876744,0.0015350372,0.00021024742,0.00042791181,0.00045148702,0.0007902883,0.0027528075],"category_scores_gemma":[0.00034205464,0.0001826722,0.000358169,0.001448054,0.00033688586,0.00077052,0.0004031163,0.0013072218,0.002143085],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009212429,0.00013969367,0.00018076597,0.008506445,0.00007115182,0.00027488393,0.000051329735,0.00031585072,0.0057662395,0.0024725378,0.018601526,0.9635275],"study_design_scores_gemma":[0.000038023973,0.00019172013,0.001137648,0.0017869736,0.0000840325,0.0020144621,0.00004198435,0.00007980035,0.0015326125,0.0013390753,0.99174225,0.000011460382],"about_ca_topic_score_codex":0.000825473,"about_ca_topic_score_gemma":0.0013176842,"teacher_disagreement_score":0.0027528075,"about_ca_system_score_codex":0.000402086,"about_ca_system_score_gemma":0.0006399113,"threshold_uncertainty_score":0.009209096},"labels":[],"label_agreement":null},{"id":"W2086311575","doi":"10.4161/hv.1.6.2377","title":"Safety and Immunogenicity of Two Formulations of a Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus-<i>Haemophilus influenzae</i>b Conjugate-Hepatitis B Vaccine in 15 to 18 Month-Old Children","year":2005,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Diphtheria; Immunogenicity; Medicine; Virology; Tetanus; Haemophilus influenzae; Conjugate vaccine; Poliovirus; Immunization; Vaccination; Microbiology; Immunology; Antibody; Antibiotics; Virus; Biology","score_opus":0.020272946423950115,"score_gpt":0.2904327260510381,"score_spread":0.270159779627088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086311575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99945563,0.000215019,0.00010304157,0.000013881616,0.000013905386,0.0000881231,0.000031828655,0.0000066613366,0.00007187208],"genre_scores_gemma":[0.9986406,0.0002698158,0.00045747717,0.000053178443,0.000032629112,0.00019034436,0.00015550871,0.0000062297518,0.00019429137],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99920505,0.00038173815,0.00006277403,0.0001298871,0.00012010359,0.0001005373],"domain_scores_gemma":[0.9989636,0.0003473776,0.00033139082,0.00009806502,0.000077976874,0.00018152346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010953216,0.0007841334,0.0009978471,0.00027694282,0.0002780776,0.00040100215,0.00052850985,0.00091616705,0.0011924993],"category_scores_gemma":[0.0017867448,0.00067030225,0.0008331736,0.00022769741,0.0009318477,0.0006451062,0.00019981008,0.0015001612,0.00025402606],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63486314,0.105218425,0.025918279,0.00082980364,0.0010154109,0.00028999918,0.00070806255,0.0013021998,0.14334403,0.0001672938,0.000394691,0.0859487],"study_design_scores_gemma":[0.047641244,0.9039822,0.026237255,0.000017289925,0.00035209925,0.00026151974,0.00009347434,0.00064583926,0.020263696,0.000049881368,0.00043502968,0.00002042484],"about_ca_topic_score_codex":0.00067698903,"about_ca_topic_score_gemma":0.0005106846,"teacher_disagreement_score":0.0011924993,"about_ca_system_score_codex":0.000439014,"about_ca_system_score_gemma":0.00057809614,"threshold_uncertainty_score":0.0057926774},"labels":[],"label_agreement":null},{"id":"W2087412934","doi":"10.4161/hv.1.5.2079","title":"Safety and Immunogenicity of a Pentavalent Combination Vaccine (Diphtheria, Tetanus, Acellular Pertussis, Polio and Haemophilus Influenzae Type b Conjugate) When Administered as a Fourth Dose at 15 to 18 Months of Age","year":2005,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Children's Hospital","funders":"Sanofi Pasteur","keywords":"Medicine; Tetanus; Diphtheria; Booster dose; Poliomyelitis; Vaccination; Immunogenicity; Immunization; Immunology; Vaccination schedule; Adverse effect; Conjugate vaccine; Haemophilus influenzae; Hib vaccine; Pediatrics; Internal medicine; Antibody; Antibiotics","score_opus":0.02343117416936941,"score_gpt":0.27510803242843257,"score_spread":0.25167685825906316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087412934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995297,0.00016952507,0.00007641298,0.000012025364,0.0000067406854,0.000026823709,0.00005807546,0.0000039016522,0.00011662949],"genre_scores_gemma":[0.9992823,0.00013572685,0.0001593699,0.000024299627,0.000015381444,0.00004490911,0.00015031059,0.0000021065594,0.00018556278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99951184,0.00019191857,0.000037134894,0.0000752413,0.00012176213,0.00006200217],"domain_scores_gemma":[0.99924904,0.00013674365,0.00028438302,0.00007508706,0.00009800992,0.00015677512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010391374,0.00037754633,0.0005413216,0.00017692032,0.00014320757,0.0002819526,0.0002905581,0.00037461362,0.00052920176],"category_scores_gemma":[0.0011972626,0.00019569354,0.00045339335,0.00015713286,0.00038813954,0.00026496188,0.0001287542,0.00060003693,0.00017346126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4907859,0.032427795,0.15503868,0.000498753,0.0008903113,0.000613062,0.0004731272,0.0021248097,0.16280125,0.00015993227,0.0007499959,0.15343638],"study_design_scores_gemma":[0.014238325,0.75980353,0.1956262,0.000041729312,0.0005137796,0.0009895194,0.00011973853,0.0016484325,0.025402322,0.00009098253,0.0015023468,0.000023197632],"about_ca_topic_score_codex":0.0010070407,"about_ca_topic_score_gemma":0.000683646,"teacher_disagreement_score":0.0010391374,"about_ca_system_score_codex":0.00036748708,"about_ca_system_score_gemma":0.0004679844,"threshold_uncertainty_score":0.0054955482},"labels":[],"label_agreement":null},{"id":"W2091731210","doi":"10.4161/hv.6.10.13018","title":"Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas","year":2010,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Dengue vaccine; Dengue fever; Context (archaeology); Clinical trial; Medicine; Meaning (existential); Dengue virus; Immunology; Psychology; Geography; Pathology","score_opus":0.04870869317239846,"score_gpt":0.3570735335645766,"score_spread":0.30836484039217815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091731210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018187593,0.8817054,0.030842392,0.05242863,0.0033599108,0.0053478717,0.00059140637,0.0001828262,0.023722794],"genre_scores_gemma":[0.01526672,0.7769805,0.1545866,0.031095061,0.00178368,0.01227363,0.00068683986,0.000116368574,0.007210632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.917561,0.051908795,0.016740786,0.0017595724,0.011400307,0.0006295208],"domain_scores_gemma":[0.8585613,0.097337976,0.015660737,0.0036936046,0.023455266,0.0012910936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12015171,0.0011427918,0.0029739903,0.0029411037,0.00096059905,0.003839081,0.004585624,0.008893238,0.0018385531],"category_scores_gemma":[0.120059095,0.001146705,0.00169721,0.0035209197,0.003216625,0.0041230326,0.0020184,0.005735813,0.0018975512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004656965,0.00025900692,0.00092445733,0.06727034,0.00026849212,0.0005407733,0.0016139406,0.0016190695,0.003284996,0.06217227,0.07732013,0.78426087],"study_design_scores_gemma":[0.00056276465,0.000504432,0.0034430507,0.07719986,0.00066164683,0.0011678167,0.0006096548,0.00072367035,0.0022358573,0.025693743,0.88707864,0.000118880715],"about_ca_topic_score_codex":0.0031071333,"about_ca_topic_score_gemma":0.0064293207,"teacher_disagreement_score":0.12015171,"about_ca_system_score_codex":0.0029016675,"about_ca_system_score_gemma":0.020700494,"threshold_uncertainty_score":0.6354306},"labels":[],"label_agreement":null},{"id":"W2114391710","doi":"10.4161/hv.5.10.9518","title":"Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years","year":2009,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gardasil; Medicine; Vaccination; Immunogenicity; HPV vaccines; Cervical cancer; Titer; Cohort; HPV infection; Virology; Immunology; Cancer; Internal medicine; Antibody","score_opus":0.045839521729254096,"score_gpt":0.37828132876353293,"score_spread":0.33244180703427884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114391710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993469,0.0002538324,0.000077636825,0.000013510997,0.000012062672,0.00006210015,0.000034260967,0.000002796316,0.00019695437],"genre_scores_gemma":[0.9991032,0.00018485644,0.00019004068,0.000045098684,0.000031191943,0.00006547992,0.00010337131,0.0000020181067,0.00027480067],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992981,0.0003651933,0.000065408116,0.000098899225,0.00011475224,0.000057670903],"domain_scores_gemma":[0.99816567,0.0007080649,0.0005134885,0.0001534748,0.00018008199,0.0002793994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014673106,0.0003085639,0.00045032977,0.00019429947,0.00012797426,0.00022063119,0.00022798851,0.00042387893,0.00075088337],"category_scores_gemma":[0.0023250433,0.00025774236,0.00046390406,0.0001356951,0.00037230318,0.00033747792,0.00015230059,0.0004455016,0.00019078533],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7511637,0.017006373,0.094898336,0.0005212006,0.00086431735,0.00009740247,0.00067671033,0.0006613714,0.057395566,0.00013261639,0.00033926926,0.07624316],"study_design_scores_gemma":[0.024608502,0.8006866,0.16277832,0.00002841609,0.00047645238,0.00022952711,0.00015980737,0.0007121164,0.009005022,0.00011784232,0.0011720617,0.000025264251],"about_ca_topic_score_codex":0.00044795228,"about_ca_topic_score_gemma":0.00038053677,"teacher_disagreement_score":0.0014673106,"about_ca_system_score_codex":0.0002088586,"about_ca_system_score_gemma":0.00030965076,"threshold_uncertainty_score":0.0077599883},"labels":[],"label_agreement":null},{"id":"W2127650449","doi":"10.4161/hv.6.6.11097","title":"Recent advances in<i>Ebolavirus</i>vaccine development","year":2010,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Viral Infections and Outbreaks Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Public Health Agency of Canada","funders":"","keywords":"Biodefense; Ebolavirus; Virology; Case fatality rate; Biology; Outbreak; Medicine; Immunology; Ebola virus; Population; Microbiology; Environmental health","score_opus":0.08233256001993501,"score_gpt":0.43321658682336983,"score_spread":0.35088402680343483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127650449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014297188,0.9980363,0.00012394952,0.0002606304,0.00016743649,0.000004984791,0.000014955166,0.000006621862,0.001242162],"genre_scores_gemma":[0.0005282383,0.9984133,0.00027597215,0.00014666474,0.0001476757,0.0000054596226,0.000026266342,0.000001243535,0.0004551448],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970454,0.000051788804,0.000050505092,0.000055928675,0.000110368295,0.000026770662],"domain_scores_gemma":[0.99915576,0.00042853152,0.00010664536,0.00002376736,0.00022591233,0.000059341975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011198401,0.00089072774,0.0012622764,0.0030074725,0.00028973154,0.0012240187,0.0008795484,0.0011268283,0.0049723275],"category_scores_gemma":[0.0014914604,0.00037543196,0.00061493035,0.0032240192,0.000467019,0.0019792279,0.0006716285,0.001536828,0.0031805206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087727145,0.00010469009,0.00022450996,0.02123787,0.00006677711,0.00016941295,0.00007214621,0.00048127162,0.0026401847,0.0028358141,0.021370914,0.9507086],"study_design_scores_gemma":[0.000015392736,0.000101500635,0.00062938157,0.0034302776,0.00008066286,0.0006224022,0.000057811376,0.00008463527,0.00090772123,0.0015682423,0.99248546,0.000016404354],"about_ca_topic_score_codex":0.001551146,"about_ca_topic_score_gemma":0.0018239086,"teacher_disagreement_score":0.0049723275,"about_ca_system_score_codex":0.0007707837,"about_ca_system_score_gemma":0.0015453544,"threshold_uncertainty_score":0.016634107},"labels":[],"label_agreement":null},{"id":"W2152769327","doi":"10.4161/hv.5.5.7607","title":"Vaccines and vaccination strategies against human cutaneous leishmaniasis","year":2009,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Research on Leishmaniasis Studies","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Vaccination; Cutaneous leishmaniasis; Immunology; Leishmaniasis; Immunity; Leishmania; Leishmania major; Immune system; Medicine; Virology; Attenuated vaccine; Disease; Biology; Virulence","score_opus":0.07216413609611459,"score_gpt":0.38866359333510864,"score_spread":0.31649945723899403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152769327","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019465778,0.9988146,0.00010769961,0.00013558351,0.00008618969,0.0000058100445,0.0000067670453,0.000004246659,0.00064449635],"genre_scores_gemma":[0.0012461809,0.9978751,0.00021116128,0.00016144643,0.00008228013,0.000010383756,0.000016067543,9.673505e-7,0.00039654467],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998344,0.000044340475,0.00002281501,0.00002901509,0.000051460724,0.000017966653],"domain_scores_gemma":[0.9998579,0.00006965064,0.000029179604,0.000005189635,0.000026996455,0.000011086024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005908596,0.000687455,0.0012077867,0.0021547005,0.00020087886,0.0005746446,0.00060624036,0.0011256348,0.0030700604],"category_scores_gemma":[0.00055162964,0.00026535423,0.00042922975,0.0013106482,0.0004907818,0.001055298,0.00041227567,0.0013480516,0.0014670932],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009872781,0.00013774722,0.00016074743,0.021197438,0.0000756784,0.00024767607,0.00007349903,0.00044892417,0.005326888,0.0042927144,0.0123784905,0.9555615],"study_design_scores_gemma":[0.000056541638,0.0003324217,0.0011479257,0.0073091546,0.00014359113,0.0026493901,0.00008669928,0.00010366892,0.0022614403,0.0029467046,0.9829444,0.000018037666],"about_ca_topic_score_codex":0.00079983316,"about_ca_topic_score_gemma":0.0009517011,"teacher_disagreement_score":0.0030700604,"about_ca_system_score_codex":0.00045766504,"about_ca_system_score_gemma":0.00057493435,"threshold_uncertainty_score":0.010270357},"labels":[],"label_agreement":null},{"id":"W2164293944","doi":"10.4161/hv.7.5.14819","title":"Burden of rotavirus gastroenteritis in the pediatric population in Central and Eastern Europe","year":2011,"lang":"en","type":"review","venue":"Human Vaccines","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inro Consultants (Canada)","funders":"","keywords":"Rotavirus; Rotavirus gastroenteritis; Medicine; Population; Virology; Pediatrics; Geography; Environmental health; Virus","score_opus":0.09505753528006307,"score_gpt":0.3736135117448424,"score_spread":0.27855597646477936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164293944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03770765,0.9586651,0.0001251444,0.0006951927,0.00008882568,0.000022894992,0.0016142734,0.000010579254,0.0010703225],"genre_scores_gemma":[0.14788046,0.8493971,0.0005049956,0.00059322466,0.00017570028,0.000045311623,0.0013039211,0.0000034030938,0.00009586965],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873036,0.00037693014,0.0004173201,0.00017058605,0.00023475746,0.00007009435],"domain_scores_gemma":[0.997623,0.0010417475,0.00085977215,0.00003745009,0.00036576085,0.0000722381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002600087,0.00049984583,0.0014545226,0.005762978,0.00016608075,0.0013151912,0.0005810568,0.00052361895,0.0013465694],"category_scores_gemma":[0.0041351854,0.00024986852,0.0012819378,0.0078043416,0.00031754753,0.00081209803,0.00050773966,0.00029930403,0.00013742341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005992414,0.00007588027,0.31200317,0.17310654,0.0124939075,0.0025870297,0.0014289682,0.0014830808,0.001481485,0.0010681712,0.012799425,0.4808731],"study_design_scores_gemma":[0.00018197075,0.0006878307,0.78094304,0.089637645,0.015240216,0.0072814245,0.0029434965,0.0003637724,0.00065407815,0.0007267372,0.10125945,0.00008045548],"about_ca_topic_score_codex":0.0050587817,"about_ca_topic_score_gemma":0.006535716,"teacher_disagreement_score":0.005762978,"about_ca_system_score_codex":0.0007000113,"about_ca_system_score_gemma":0.0020222457,"threshold_uncertainty_score":0.013750732},"labels":[],"label_agreement":null},{"id":"W2416299241","doi":"10.4161/hv.7.0.14904","title":"Preface: Seventh World Congress on Vaccines, Immunisation and Immunotherapy","year":2011,"lang":"en","type":"article","venue":"Human Vaccines","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"International Civil Aviation Organization","funders":"","keywords":"Library science; Vaccination; Medicine; Political science; Family medicine; Immunology","score_opus":0.05717104425724771,"score_gpt":0.3054764996989979,"score_spread":0.2483054554417502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416299241","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037269495,0.018308701,0.00056474964,0.034613073,0.9092789,0.00027931575,0.0006815605,0.0001872096,0.035713773],"genre_scores_gemma":[0.0032405544,0.029130487,0.00072780787,0.018747095,0.7165487,0.00042734237,0.0027815432,0.00030484723,0.22809166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982535,0.00027269666,0.00016602187,0.00020004986,0.0008829493,0.00022469676],"domain_scores_gemma":[0.9934549,0.00082350156,0.00053628493,0.00025959415,0.0029899068,0.0019359551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033444865,0.0028663871,0.0019648813,0.0032208152,0.0018551968,0.0072167334,0.002173944,0.0048009343,0.075613916],"category_scores_gemma":[0.0058944905,0.0005204885,0.0011676408,0.0015318,0.00087948766,0.0034315735,0.002058576,0.006493515,0.0603593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054616077,0.000035008867,0.00006287657,0.00019223704,0.0000052258433,0.000031182848,0.000015456944,0.00003641214,0.00019635208,0.0003856159,0.9799043,0.019080836],"study_design_scores_gemma":[0.000010100238,0.000036466685,0.0004688112,0.00014335611,0.000005158234,0.000050933693,0.000025678226,0.000040795087,0.000102639075,0.00034401333,0.9987639,0.000008096041],"about_ca_topic_score_codex":0.0015822479,"about_ca_topic_score_gemma":0.0021044551,"teacher_disagreement_score":0.075613916,"about_ca_system_score_codex":0.0019279125,"about_ca_system_score_gemma":0.003094191,"threshold_uncertainty_score":0.25295377},"labels":[],"label_agreement":null}]}